MX2020007283A - Derivados de acido 3-fenil-4-hexinoico como agonistas del receptor acoplado a la proteina g-40. - Google Patents

Derivados de acido 3-fenil-4-hexinoico como agonistas del receptor acoplado a la proteina g-40.

Info

Publication number
MX2020007283A
MX2020007283A MX2020007283A MX2020007283A MX2020007283A MX 2020007283 A MX2020007283 A MX 2020007283A MX 2020007283 A MX2020007283 A MX 2020007283A MX 2020007283 A MX2020007283 A MX 2020007283A MX 2020007283 A MX2020007283 A MX 2020007283A
Authority
MX
Mexico
Prior art keywords
phenyl
acid derivatives
hexynoic acid
gpr40 agonists
unsaturated
Prior art date
Application number
MX2020007283A
Other languages
English (en)
Inventor
Mikolaj Matloka
Maciej Wieczorek
Krzysztof Dubiel
Jerzy Pieczykolan
Mateusz Mach
Radoslaw Dzida
Damian Smuga
Filip Stelmach
Katarzyna Bazydlo
Original Assignee
Celon Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PL424227A external-priority patent/PL233938B1/pl
Application filed by Celon Pharma Sa filed Critical Celon Pharma Sa
Publication of MX2020007283A publication Critical patent/MX2020007283A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C07C57/60—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un compuesto de la formula (I) en donde R representa un grupo de C3 - C15 de hidrocarbilo aciclico primario o secundario, lineal o ramificado, que puede estar saturado o insaturado, o un grupo de C3 - C15 de hidrocarbilo aciclico primario o secundario, lineal o ramificado, que puede estar saturado o insaturado y en donde uno o más de los átomos de hidrogeno se reemplazan con átomos de flúor; X representa un átomo de hidrogeno o un átomo de halógeno, y * indica el centro quiral y sus sales; el compuesto es útil para el tratamiento de enfermedades mediadas por el GPR40, en particular diabetes tipo II.
MX2020007283A 2018-01-08 2019-01-07 Derivados de acido 3-fenil-4-hexinoico como agonistas del receptor acoplado a la proteina g-40. MX2020007283A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL424227A PL233938B1 (pl) 2018-01-08 2018-01-08 Pochodne kwasu 3-fenylo-4-heksynowego jako agoniści GPR40
PL42562518 2018-05-18
PCT/EP2019/050194 WO2019134984A1 (en) 2018-01-08 2019-01-07 3-phenyl-4-hexynoic acid derivatives as gpr40 agonists

Publications (1)

Publication Number Publication Date
MX2020007283A true MX2020007283A (es) 2020-09-10

Family

ID=67144423

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007283A MX2020007283A (es) 2018-01-08 2019-01-07 Derivados de acido 3-fenil-4-hexinoico como agonistas del receptor acoplado a la proteina g-40.

Country Status (14)

Country Link
US (1) US11964938B2 (es)
EP (1) EP3737470B9 (es)
JP (1) JP7289305B2 (es)
KR (1) KR102705659B1 (es)
CN (1) CN111757770B (es)
AU (1) AU2019205093B2 (es)
BR (1) BR112020013694A2 (es)
DK (1) DK3737470T5 (es)
ES (1) ES2939720T3 (es)
FI (1) FI3737470T3 (es)
MX (1) MX2020007283A (es)
PL (1) PL3737470T3 (es)
PT (1) PT3737470T (es)
WO (1) WO2019134984A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022006546A2 (pt) 2019-10-07 2022-08-30 Kallyope Inc Agonistas de gpr119
CA3173731A1 (en) 2020-02-28 2021-09-02 Kallyope, Inc. Gpr40 agonists
CN116323608A (zh) 2020-05-19 2023-06-23 卡尔优普公司 Ampk活化剂
EP4172162A4 (en) 2020-06-26 2024-08-07 Kallyope, Inc. AMPK ACTIVATORS
CN121729216A (zh) * 2023-08-11 2026-03-24 生命密码有限公司 促进毛发生长和/或减轻脱发的组合物、药剂和制剂
CN117343066A (zh) * 2023-09-05 2024-01-05 华南师范大学 喹唑啉酮生物碱Brevianamide M衍生物及制备方法与抗炎抗肿瘤应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1559422B1 (en) 2002-11-08 2014-04-30 Takeda Pharmaceutical Company Limited Receptor function controlling agent
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
CA2551610A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
EA011010B1 (ru) * 2004-02-27 2008-12-30 Эмджен, Инк. Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина
WO2005087710A1 (ja) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
US7989457B2 (en) 2004-05-28 2011-08-02 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
CL2007001873A1 (es) 2006-06-27 2008-01-04 Takeda Pharmaceutical Acido((3s))-6-((¨2,6-dimetil-4-(3-(metilsulfonil)-propoxi)bifenil-3-il)metoxi-2,3-dihidro-1-benzofuran-3-il)acetico o una sal del mismo
AU2007293028B2 (en) 2006-09-07 2012-05-31 Amgen Inc. Heterocyclic GPR40 modulators
US7750048B2 (en) 2006-11-15 2010-07-06 Janssen Pharmaceutica Nv GPR40 agonists
CA2683751C (en) 2007-04-16 2013-01-08 Amgen Inc. Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
WO2010143733A1 (en) 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
RU2627703C2 (ru) 2010-07-23 2017-08-10 Конекшис Лайф Сайенсиз Пвт. Лтд. Агонисты gpr40
CN104470886A (zh) 2011-04-08 2015-03-25 赛丹思科大学 用于治疗代谢疾病的邻-氟取代的化合物
AR087451A1 (es) 2011-08-17 2014-03-26 Lilly Co Eli Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
US9238639B2 (en) 2012-02-24 2016-01-19 Takeda Pharmaceutical Company Limited Aromatic ring compound
TW201341356A (zh) 2012-02-28 2013-10-16 皮拉馬爾企業有限公司 作為gpr促效劑之苯基烷酸衍生物
KR20160095117A (ko) 2014-01-10 2016-08-10 일라이 릴리 앤드 캄파니 페닐-트리아졸로-피리딘 화합물
CA2960944C (en) * 2014-10-17 2019-09-10 Hyundai Pharm Co., Ltd. Use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivatives in combination with a secondary active ingredient for the treatment of metabolic diseases

Also Published As

Publication number Publication date
JP7289305B2 (ja) 2023-06-09
FI3737470T3 (fi) 2023-03-19
AU2019205093B2 (en) 2024-03-07
EP3737470A1 (en) 2020-11-18
DK3737470T5 (da) 2024-05-27
CN111757770B (zh) 2023-10-03
AU2019205093A1 (en) 2020-07-16
US11964938B2 (en) 2024-04-23
WO2019134984A1 (en) 2019-07-11
EP3737470B9 (en) 2024-03-13
EP3737470B1 (en) 2022-12-14
JP2021509909A (ja) 2021-04-08
ES2939720T3 (es) 2023-04-26
KR102705659B1 (ko) 2024-09-11
PL3737470T3 (pl) 2023-05-08
DK3737470T3 (da) 2023-03-13
CA3087712A1 (en) 2019-07-11
BR112020013694A2 (pt) 2020-12-01
US20200399198A1 (en) 2020-12-24
KR20200108318A (ko) 2020-09-17
ES2939720T9 (es) 2024-06-04
PT3737470T (pt) 2023-03-02
CN111757770A (zh) 2020-10-09

Similar Documents

Publication Publication Date Title
ZA202310378B (en) Complement factor b inhibitor, and pharmaceutical composition thereof, preparation method therefor and use thereof
CR20220354A (es) Inhibidores de egfr
CR20240147A (es) Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t
MX2021003459A (es) Proceso de fabricacion de un compuesto para la inhibicion de la actividad de shp2.
MX2024000230A (es) Inhibidores de cdk2.
MX2025008591A (es) Inhibidores de cdk
ZA202007566B (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
MX2022003018A (es) Danavorexton (tak-925) para usarse en el tratamiento de la narcolepsia.
SA523451905B1 (ar) Cdk2 مركبات بيريميدينيل-بيرازول بها استبدال كمثبطات
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
WO2018125983A8 (en) Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors
MX2023000970A (es) Metodo de preparacion de aminofuranos.
EA202190880A1 (ru) Кристаллическая форма морфолинохиназолинового соединения, способ ее получения и ее применение
MX2018005244A (es) Composiciones de tratamiento y metodos de tratamiento de un sustrato.
NZ780304A (en) Uses of phosphodiesterase inhibitors
MY147951A (en) Crystalline potassium salt of lipoxin a? analogs
CL2024003171A1 (es) Gamma-hidroxibutirato que administra compuestos y procesos para su fabricación y uso
AR118647A1 (es) Proceso de preparación de 2-(3,5-diclorofenil)-6-benzoxazolcarboxilato de 1-deoxi-1-metilamino-d-glucitol
MX2024012267A (es) Inhibidores de egfr
MX2020010394A (es) Composicion repelente de insectos que comprende uno o mas acidos grasos repelentes de insectos que tienen entre 9 y 21 atomos de carbono.
NZ782087A (en) Feed composition comprising hexahydro-β-acid component compounds and application thereof
MY209356A (en) A xinafoate salt of a jak inhibiting compound
BR112023018246A2 (pt) Formas de sal e sólidas de um inibidor de cinase
EA202091211A1 (ru) Производные 3-фенил-4-гексиновой кислоты как агонисты gpr40
GEP20267875B (en) Processes for the preparation of a kinase inhibitor